| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥5494.6B | ¥5831.9B | -5.8% |
| Operating Income | ¥378.0B | ¥452.9B | -16.5% |
| Ordinary Income | ¥481.7B | ¥538.5B | -10.6% |
| Net Income | ¥-211.1B | ¥407.4B | -151.8% |
| ROE | -3.1% | 5.8% | - |
FY2025 Q3 cumulative results show revenue of 549.5B yen (YoY -5.8%), operating income of 37.8B yen (YoY -16.5%), ordinary income of 48.2B yen (YoY -10.6%), and net loss of -21.1B yen (YoY -151.8%). The significant deterioration from profit to loss was driven by substantial impairment losses totaling 59.5B yen recorded in the current period, primarily in the Green Energy and Chemicals segment (53.5B yen) and Specialty Chemicals segment (6.0B yen). Operating margin declined to 6.9% from 7.8% in the prior year, reflecting both top-line contraction and profitability pressure in the Green Energy and Chemicals business.
Revenue declined 5.8% YoY to 549.5B yen, with the Green Energy and Chemicals Business Sector falling 11.6% to 209.3B yen and Specialty Chemicals Business Sector decreasing 1.3% to 331.7B yen. The Green Energy and Chemicals segment experienced substantial margin compression, with segment ordinary income declining 48.9% to 9.4B yen from 18.4B yen in the prior year, indicating deteriorating profitability in this business line. In contrast, the Specialty Chemicals segment maintained stable profitability with segment ordinary income of 38.7B yen, essentially flat compared to 38.5B yen in the prior year, demonstrating resilience despite modest revenue decline. Operating income decreased 16.5% to 37.8B yen, with operating margin compressing 0.9 percentage points to 6.9%. The gap between operating income (37.8B yen) and ordinary income (48.2B yen) of 10.4B yen reflects net non-operating gains, primarily equity method investment income, dividend income of 3.7B yen, interest income of 1.1B yen, and foreign exchange gains of 4.5B yen. The critical divergence between ordinary income (48.2B yen) and net loss (-21.1B yen) represents a 69.3B yen gap, predominantly attributable to non-recurring impairment losses of 59.5B yen (53.5B yen in Green Energy and Chemicals, 6.0B yen in Specialty Chemicals). This represents a revenue down, profit down pattern, with the profit decline amplified by non-recurring impairment charges reflecting asset revaluation in the Green Energy business.
The Green Energy and Chemicals Business Sector generated revenue of 209.3B yen (down 11.6% YoY) with segment ordinary income of 9.4B yen (down 48.9% YoY), representing a segment margin of 4.5%. The Specialty Chemicals Business Sector, which constitutes the core business with 60.4% of total external sales, recorded revenue of 331.7B yen (down 1.3% YoY) with segment ordinary income of 38.7B yen (up 0.4% YoY), representing a segment margin of 11.7%. The material margin difference between segments indicates that Specialty Chemicals operates with approximately 2.6 times higher profitability than Green Energy and Chemicals. The Other Business segment contributed 8.4B yen in revenue with segment ordinary income of 1.1B yen. The substantial impairment of 53.5B yen in Green Energy and Chemicals reflects significant asset write-downs, suggesting structural challenges in this segment's earnings capacity.
[Profitability] ROE is -3.9%, deteriorating from positive territory in prior periods, primarily driven by the net loss. Operating margin of 6.9% represents a 0.9 percentage point decline from 7.8% YoY. Net profit margin of -4.8% reflects the impact of non-recurring impairments. [Cash Quality] Cash and deposits total 69.5B yen, providing coverage of 0.95 times against short-term debt of 73.6B yen, indicating tight but adequate short-term liquidity. [Investment Efficiency] Total asset turnover of 0.49 reflects capital-intensive operations. Return on assets is -1.9%, impacted by the net loss. [Financial Health] Equity ratio stands at 60.2%, down from 62.3% in the prior period but remaining conservative. Current ratio of 165.8% and quick ratio of 124.2% demonstrate satisfactory liquidity. Debt-to-equity ratio of 0.22 indicates low financial leverage, with interest-bearing debt of 145.2B yen against total equity of 670.5B yen.
Cash and deposits decreased 12.2B yen YoY to 69.5B yen, reflecting cash consumption during the period. Working capital shows deterioration with accounts receivable increasing to 157.1B yen and inventory rising across raw materials (57.5B yen), work in progress (48.0B yen), and finished goods (106.3B yen), totaling 211.8B yen in inventory. Operating working capital expanded significantly to 184.8B yen, suggesting extended cash conversion cycles. The increase in inventory levels combined with declining revenue indicates potential overstocking or demand softness requiring management attention. Accounts payable of 115.4B yen provides partial funding for working capital needs. Investment securities holdings of 303.1B yen represent substantial non-operating assets. The cash coverage ratio of 0.95 against short-term liabilities indicates the company relies on operating cash generation and credit facilities to meet near-term obligations.
Ordinary income of 48.2B yen versus operating income of 37.8B yen reflects net non-operating gains of approximately 10.4B yen, comprising equity method investment gains, dividend income of 3.7B yen, interest income of 1.1B yen, and foreign exchange gains of 4.5B yen. Non-operating income represents approximately 1.9% of revenue, providing meaningful support to headline profitability. The substantial gap between ordinary income (48.2B yen) and net loss (-21.1B yen) stems from extraordinary losses totaling 61.0B yen, dominated by impairment charges of 59.5B yen. These impairments represent 10.8% of revenue and 240.9% of the absolute value of net income, indicating earnings quality is significantly compromised by non-recurring factors in the current period. The recurring earnings base, proxied by ordinary income, suggests underlying business profitability remains positive despite top-line pressure, but the magnitude of asset write-downs raises questions about prior period asset valuations and future earning power of impaired assets.
The company forecasts full-year revenue of 730.0B yen, operating income of 47.0B yen, ordinary income of 55.0B yen, and net loss of -18.0B yen. Q3 cumulative progress rates stand at 75.3% for revenue, 80.4% for operating income, and 87.6% for ordinary income, all tracking ahead of the standard 75% benchmark for Q3. However, the net loss of -21.1B yen already exceeds the full-year loss guidance of -18.0B yen, suggesting either Q4 recovery is expected or guidance may require downward revision. The full-year guidance implies YoY declines of -5.6% in revenue, -7.6% in operating income, and -8.8% in ordinary income. The elevated progress rates for operating and ordinary income relative to revenue suggest margin improvement is anticipated in Q4, though the net loss overshoot indicates uncertainty around the profit recovery trajectory.
Annual dividend of 50 yen per share is maintained according to full-year guidance. Based on the forecasted net loss of -18.0B yen, the payout ratio calculation is not meaningful as net income is negative. The commitment to maintaining dividends despite projected losses suggests management confidence in underlying cash generation capacity, though sustainability warrants monitoring given the negative earnings outlook. No share buyback activity is disclosed in the available data.
Asset impairment risk remains elevated as evidenced by 59.5B yen in impairment losses recorded in Q3, particularly concentrated in the Green Energy and Chemicals segment at 53.5B yen, indicating ongoing challenges in earning asset returns and potential for additional write-downs if business conditions deteriorate further. Working capital deterioration poses liquidity risk with inventory increasing to 211.8B yen while revenue declined 5.8% YoY, and accounts receivable at 157.1B yen suggesting extended collection cycles or demand softness that could pressure operating cash flow. Short-term refinancing risk exists with short-term debt of 73.6B yen representing 50.7% of total liabilities and cash coverage at 0.95 times, creating exposure to funding market conditions and requiring active liability management to maintain liquidity.
[Industry Position] (Reference - Proprietary Analysis) Profitability: Operating Margin 6.9% (Industry Median 8.7%, positioned below median), Net Profit Margin -4.8% (Industry Median 6.4%, significantly below median due to impairments), ROE -3.9% (Industry Median 5.2%, substantially below median reflecting current period loss). Financial Health: Equity Ratio 60.2% (Industry Median 63.8%, slightly below median but within healthy range), Current Ratio 165.8% (Industry Median 283%, below median indicating tighter liquidity positioning). Efficiency: Asset Turnover 0.49 (Industry Median 0.58, below median reflecting capital intensity), Receivables Turnover 104.4 days (Industry Median 82.9 days, slower collection), Inventory Turnover 140.8 days (Industry Median 108.8 days, elevated inventory levels), Operating Working Capital Turnover 122.8 days (Industry Median 108.1 days, indicating working capital efficiency below industry standard). The company's profitability metrics fall below manufacturing sector medians, with particular weakness in net profitability due to non-recurring impairments. Working capital efficiency indicators suggest operational challenges with extended cash conversion cycles relative to industry peers. Financial leverage remains conservative, though liquidity positioning is tighter than typical manufacturing peers. (Industry: Manufacturing (n=100 companies), Comparison: 2025-Q3 fiscal period, Source: Proprietary analysis)
The earnings results reveal three significant characteristics warranting attention. First, the company experienced substantial asset impairment charges totaling 59.5B yen concentrated in the Green Energy and Chemicals segment, representing 10.8% of revenue and indicating material reassessment of asset values and future earning capacity in this business line. Second, working capital deterioration is evident with inventory rising to 211.8B yen and receivables at 157.1B yen despite 5.8% revenue decline, resulting in cash conversion cycle extension to 122.8 days versus industry median of 108.1 days, suggesting operational efficiency challenges that may pressure cash generation. Third, the Specialty Chemicals segment demonstrates resilience as the core business with 60.4% of revenue and stable segment profitability of 38.7B yen (segment margin 11.7%), contrasting sharply with Green Energy and Chemicals where profitability declined 48.9% to 9.4B yen (segment margin 4.5%), indicating divergent segment trajectories that merit monitoring for portfolio strategy implications.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.